Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

$V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.$
FDA panel votes against approving first-of-its-kind heart failure device
All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell.
Stem cell company acquires 2 cardiology practices, calling them ‘the first of many’
Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform.
‘Beer belly’ associated with multiple heart risks, especially in men
Abdominal obesity, the phenomenon commonly known as “beer belly," may be associated with significant risks, including heart failure. Researchers urged cardiologists and radiologists alike to keep these findings in mind going forward.
Adjustable interatrial shunt for heart failure shows promise in first-in-human trial
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
Oral heart failure drug receives FDA’s fast track designation
A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.

Cardiologist-founded virtual cardiology clinic raises $8M to expand heart failure offerings

The company hopes this new round of funding from private-equity investors will help its home-based care model flourish and reach more patients than ever before.

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects.

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

FDA warns Abiomed about ‘significant violations’ related to its Impella heart pumps

The agency said Abiomed did not seek the necessary approvals for one Impella-related device and was slow to act on certain safety concerns.

Endotronix gains key approval from FDA, shares new heart failure data

The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure.

CBD could be beneficial for some heart failure patients

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

Patisiran, marketed under the name Onpattro

FDA chooses not to approve patisiran for treating ATTR cardiomyopathy

The announcement came just weeks after an FDA subcommittee voted in favor of approval.

What is CKM syndrome? American Heart Association outlines how to identify and manage a dangerous new condition

The American Heart Association has developed an updated strategy for the prevention and management of cardiovascular disease. A newly defined health condition, cardiovascular-kidney-metabolic syndrome, sits at the center of that strategy.

Artificial intelligence (AI) is being developed to help make cardiovascular clinical trials more efficient, lead to faster advances in patient care, and bring possible new treatments to heart patients more quickly. The major cardiac research center of Icahn School of Medicine at Mount Sinai announced today that it signed a memorandum of understanding with the Chiba Institute of Technology (CIT) to collaborate on using AI to enhance cardiovascular disease research.

Mount Sinai partners with the Chiba Institute of Technology on AI to transform cardiovascular research

Agreement aims to use AI to help make cardiology clinical trials more efficient and lead to faster advances in patient care.

Heart Failure

FDA panel votes against approving first-of-its-kind heart failure device

Stem cell company acquires 2 cardiology practices, calling them ‘the first of many’

‘Beer belly’ associated with multiple heart risks, especially in men

Adjustable interatrial shunt for heart failure shows promise in first-in-human trial

Oral heart failure drug receives FDA’s fast track designation